Aphios has developed SuperFluids™ (supercritical, near-critical or critical fluids with or without polar cosolvents) technologies and designed specialized equipment for the discovery and manufacturing of natural pharmaceuticals such as the anticancer drugs paclitaxel and bryostatin, nanotechnology drug delivery of proteins, siRNA and hydrophobic small molecules, and the pathogenic safety of human plasma and monoclonal antibodies.
We have also developed SuperFluids™ technologies and designed specialized equipment for microbial cell disruption, crystallization of natural products and lipophilic peptides, and biomass pretreatment for the manufacture of biofuels and biochemicals.
SuperFluids™ CXP Semi-Works
SuperFluids™ Research-Scale, Pilot-Scale and Commercial Units
We will custom design and construct research-scale, pilot-scale and semi-works and commercial-scale units for your evaluation and utilization. We will also provide service and maintenance contracts for the equipment and provide employee training during the technology transfer phase, which will include operating and maintenance manuals.
We will custom design units listed in the table below; follow the links for further information on the enabling technology platform.
* If on a mobile device, please swipe left or right to view the entire table.
Technology Platform | Acronym | Research | Pilot | Commercial |
Drug Discovery | CXF | ✔ | ||
Drug Manufacturing | CXP | ✔ | ✔ | ✔ |
Protein Nanoparticles | PNP | ✔ | ✔ | |
Polymeric Nanospheres | PNS | ✔ | ✔ | ✔ |
Phospholipid Nanosomes | CFN | ✔ | ✔ | ✔ |
Drug Safety (Pathogen Inactivation) | CFI | ✔ | ✔ | |
Microbial Cell Disruption | CFD | ✔ | ✔ | |
Crystallization | CRY | ✔ | ✔ | |
Biomass Pretreatment | CBP | ✔ | ✔ | ✔ |